TTR and Thrombocytopenia: Thrombocytopenia was also observed for anti-sense oligonucleotide (ASO) administered at doses above 200 mg/kg, which resulted in a halt in both the IONIS CARDIO-TTR and the NEURO-TTR phase III trials, and could be traced to the phosphorothioate (PS) backbone modification [53].